FDA Approves Subcutaneous SKYRIZI for Crohn's Disease Induction

The FDA has approved AbbVie's subcutaneous induction regimen for SKYRIZI in treating Crohn's disease, allowing patients to start treatment at home instead of an infusion center. This approval follows a Phase 3 trial showing high remission rates in biologic-naive patients and introduces a new practical standard for clinical trials and treatment convenience.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.